MX2022003442A - Composiciones de trazodona pediatrica y metodo de tratamiento con las mismas. - Google Patents

Composiciones de trazodona pediatrica y metodo de tratamiento con las mismas.

Info

Publication number
MX2022003442A
MX2022003442A MX2022003442A MX2022003442A MX2022003442A MX 2022003442 A MX2022003442 A MX 2022003442A MX 2022003442 A MX2022003442 A MX 2022003442A MX 2022003442 A MX2022003442 A MX 2022003442A MX 2022003442 A MX2022003442 A MX 2022003442A
Authority
MX
Mexico
Prior art keywords
pediatric
trazodone
treatment
compositions
relates
Prior art date
Application number
MX2022003442A
Other languages
English (en)
Spanish (es)
Inventor
Serena Tongiani
Lorella Ragni
Fabrizio Calisti
Rossella Picollo
Laura Oggianu
Original Assignee
Angelini S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angelini S P A filed Critical Angelini S P A
Publication of MX2022003442A publication Critical patent/MX2022003442A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022003442A 2019-09-26 2020-09-25 Composiciones de trazodona pediatrica y metodo de tratamiento con las mismas. MX2022003442A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962906166P 2019-09-26 2019-09-26
PCT/EP2020/077017 WO2021058810A1 (en) 2019-09-26 2020-09-25 Pediatric trazodone compositions and method of treatment thereof

Publications (1)

Publication Number Publication Date
MX2022003442A true MX2022003442A (es) 2022-07-11

Family

ID=72665264

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003442A MX2022003442A (es) 2019-09-26 2020-09-25 Composiciones de trazodona pediatrica y metodo de tratamiento con las mismas.

Country Status (13)

Country Link
US (1) US12514856B2 (enExample)
EP (1) EP4034117A1 (enExample)
JP (1) JP7629453B2 (enExample)
KR (1) KR102936358B1 (enExample)
CN (1) CN114615983A (enExample)
AU (1) AU2020354534B2 (enExample)
BR (1) BR112022005343A2 (enExample)
CA (1) CA3153639A1 (enExample)
GE (2) GEP20257739B (enExample)
IL (1) IL291548A (enExample)
MX (1) MX2022003442A (enExample)
UA (1) UA129270C2 (enExample)
WO (1) WO2021058810A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240173315A1 (en) * 2022-11-14 2024-05-30 OWP Pharmaceuticals, Inc. Trazodone oral solution
US20240390277A1 (en) * 2023-04-15 2024-11-28 Rubicon Research Private Limited Liquid formulations of trazodone
CN119280155B (zh) * 2024-12-11 2025-02-25 新基元(北京)医药科技有限公司 一种改善稳定性的盐酸曲唑酮液体药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1931346T1 (sl) 2005-09-09 2012-10-30 Angelini Labopharm Llc Trazodonski sestavek za dajanje enkrat dnevno
ITMI20071573A1 (it) * 2007-07-31 2009-02-01 Acraf Composizione farmaceutica liquida stabile a base di trazodone
ITMI20071603A1 (it) 2007-08-03 2009-02-04 Acraf Trazodone e trazodone cloridrato in forma purificata

Also Published As

Publication number Publication date
JP2022549473A (ja) 2022-11-25
IL291548A (en) 2022-05-01
JP7629453B2 (ja) 2025-02-13
CA3153639A1 (en) 2021-04-01
GEAP202415936A (en) 2024-10-28
WO2021058810A1 (en) 2021-04-01
BR112022005343A2 (pt) 2022-06-14
GEP20257739B (en) 2025-02-25
US12514856B2 (en) 2026-01-06
KR102936358B1 (ko) 2026-03-10
EP4034117A1 (en) 2022-08-03
KR20220080096A (ko) 2022-06-14
US20220331312A1 (en) 2022-10-20
UA129270C2 (uk) 2025-03-05
AU2020354534B2 (en) 2025-10-02
CN114615983A (zh) 2022-06-10
AU2020354534A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
CO2022018811A2 (es) Inhibidores de la proteína kras g12c y usos de estos
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
PE20170673A1 (es) Terapia de combinacion para tratar una paramixovirus
AR122380A1 (es) Uso de inhibidores de sglt-2 para la prevención y/o tratamiento de enfermedades cardíacas en felinos
PE20190338A1 (es) Metodos de tratamiento de trastornos del desarrollo con gaboxadol
CO2020016677A2 (es) Tiofencarboxamidas sustituidas y análogos de las mismas
JOP20220259A1 (ar) تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها
AR104173A1 (es) Variantes de protoxina ii y métodos de uso
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
MX378266B (es) Inhibidores de gingipaina de lisina.
MX2024010236A (es) Akkermansia para prevenir y/o tratar trastornos de desregulación de la recompensa.
PE20180928A1 (es) Sales y profarmacos de 1-metil-d-triptofano
CL2021001554A1 (es) Métodos para el tratamiento de discinesia en parálisis cerebral.
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia
MX2021013833A (es) Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
CL2020001353A1 (es) Pirazolopirimidinas que tienen actividad contra el vsr.
BR112022005343A2 (pt) Trazodona ou um sal da mesma para uso em um método para tratar insônia, composição farmacêutica, xarope, e, método para tratar insônia
MX391376B (es) Composiciones de la membrana de la cáscara del huevo para usarse en el tratamiento de la cadena ligera kappa del factor nuclear de las células b activadas (nf-kb) en un organismo hospedero.
CO2023003129A2 (es) Vacunas contra infecciones por sars-cov-2
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
WO2020055547A3 (en) Methods and compositions for honey bee health
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.